HK1176075A1 - Antibody glycosylation in the variable region - Google Patents

Antibody glycosylation in the variable region

Info

Publication number
HK1176075A1
HK1176075A1 HK13103092.6A HK13103092A HK1176075A1 HK 1176075 A1 HK1176075 A1 HK 1176075A1 HK 13103092 A HK13103092 A HK 13103092A HK 1176075 A1 HK1176075 A1 HK 1176075A1
Authority
HK
Hong Kong
Prior art keywords
variable region
antibody glycosylation
glycosylation
antibody
variable
Prior art date
Application number
HK13103092.6A
Other languages
English (en)
Chinese (zh)
Inventor
．洛茨西爾
．赫伯
．舒鮑爾
．魏爾
．布洛克豪斯
．寶曼
．科爾
．紹布瑪
．蘭奇
Original Assignee
豪夫邁‧羅氏有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 豪夫邁‧羅氏有限公司 filed Critical 豪夫邁‧羅氏有限公司
Publication of HK1176075A1 publication Critical patent/HK1176075A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
HK13103092.6A 2005-12-12 2009-07-17 Antibody glycosylation in the variable region HK1176075A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05027090 2005-12-12

Publications (1)

Publication Number Publication Date
HK1176075A1 true HK1176075A1 (en) 2013-07-19

Family

ID=37745986

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13103092.6A HK1176075A1 (en) 2005-12-12 2009-07-17 Antibody glycosylation in the variable region
HK09106521.6A HK1130066A1 (en) 2005-12-12 2009-07-17 Antibody glycosylation in the variable region

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK09106521.6A HK1130066A1 (en) 2005-12-12 2009-07-17 Antibody glycosylation in the variable region

Country Status (34)

Country Link
US (2) US8906370B2 (xx)
EP (2) EP2377886A1 (xx)
JP (1) JP5145241B2 (xx)
KR (2) KR101401159B1 (xx)
CN (2) CN101351476B (xx)
AR (1) AR057233A1 (xx)
AT (1) ATE517923T1 (xx)
AU (1) AU2006326301B2 (xx)
BR (1) BRPI0619605B8 (xx)
CA (1) CA2632828C (xx)
CR (1) CR10000A (xx)
CY (1) CY1114783T1 (xx)
DK (1) DK1960428T3 (xx)
DO (1) DOP2006000278A (xx)
EC (1) ECSP088524A (xx)
ES (1) ES2368591T3 (xx)
HK (2) HK1176075A1 (xx)
IL (1) IL191004A (xx)
JO (1) JO2824B1 (xx)
MA (1) MA30038B1 (xx)
MY (1) MY155286A (xx)
NO (1) NO346105B1 (xx)
NZ (1) NZ568241A (xx)
PE (3) PE20100684A1 (xx)
PL (1) PL1960428T3 (xx)
PT (1) PT1960428E (xx)
RS (1) RS52004B (xx)
RU (1) RU2438706C2 (xx)
SI (1) SI1960428T1 (xx)
TW (1) TWI382990B (xx)
UA (1) UA99097C2 (xx)
UY (1) UY30003A1 (xx)
WO (1) WO2007068429A1 (xx)
ZA (1) ZA200805038B (xx)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CN101432302A (zh) 2005-11-30 2009-05-13 艾博特公司 抗－Aβ球聚体抗体，其抗原结合部分，相应的杂交瘤、核酸、载体、宿主细胞，生产所述抗体的方法，包含所述抗体的组合物，所述抗体的应用以及使用所述抗体的方法
CA2631195C (en) 2005-11-30 2016-04-05 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
PT1960428E (pt) * 2005-12-12 2011-10-07 Hoffmann La Roche Anticorpos glicosilados na região variável contra beta-amilóide 4
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PE20081477A1 (es) * 2006-12-11 2008-10-18 Hoffmann La Roche Formulacion liofilizada mab abeta
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
SI2167540T1 (en) * 2007-06-29 2018-05-31 F. Hoffmann-La Roche Ag A mutant heavy chain that enables improved production of immunoglobulins
KR101637533B1 (ko) 2007-08-20 2016-07-11 글락소 그룹 리미티드 제조 방법
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
RS53551B1 (en) * 2007-12-21 2015-02-27 F. Hoffmann La Roche Ag ANTIBODY FORMULATION
PL2282773T3 (pl) * 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
US20120282654A1 (en) * 2009-04-29 2012-11-08 Schering Corporation Antibody purification
WO2011090720A2 (en) * 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd Purification of proteins
TW201144437A (en) 2010-03-03 2011-12-16 Boehringer Ingelheim Int A-beta binding polypeptides
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
CN104023743B (zh) * 2011-10-25 2017-05-03 普罗西纳治疗有限公司 抗体制剂和方法
CN103998930A (zh) * 2011-12-02 2014-08-20 普拉希京公司 用于形成和检测斑块的斑块阵列方法和组合物
HUE028440T2 (en) 2012-03-08 2016-12-28 Hoffmann La Roche Abeta antibody preparation
EP3315514A1 (en) * 2012-08-29 2018-05-02 F. Hoffmann-La Roche AG Blood brain barrier shuttle
CN102998454A (zh) * 2012-12-11 2013-03-27 华中师范大学 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法
EP2934589B1 (en) * 2012-12-18 2021-01-13 The Rockefeller University Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
JP6169885B2 (ja) 2013-05-07 2017-07-26 株式会社日立製作所 精製装置及び精製方法
SG10201802525QA (en) 2013-09-13 2018-04-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
JP6086566B2 (ja) 2013-11-22 2017-03-01 国立大学法人 東京大学 薬剤送達用のキャリア、コンジュゲートおよびこれらを含んでなる組成物並びにこれらの投与方法
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CA2985718A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
MX2018001536A (es) * 2015-08-21 2018-04-24 Hoffmann La Roche Metodo para la reduccion de proteinas de celulas hospederas en cromatografia de afinidad.
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
HUE057085T2 (hu) * 2015-10-16 2022-04-28 Hoffmann La Roche Egy rendszer mûködtetésére szolgáló eljárás és egy rendszer
JP7448174B2 (ja) 2015-11-09 2024-03-12 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
KR20180094876A (ko) 2015-11-09 2018-08-24 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
US10792477B2 (en) * 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
WO2017153848A1 (en) * 2016-03-10 2017-09-14 Genomic Vision Method of curvilinear signal detection and analysis and associated platform
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
WO2018014126A1 (en) 2016-07-18 2018-01-25 The University Of British Columbia Antibodies to amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US20200113854A1 (en) * 2017-05-30 2020-04-16 Morinaga Milk Industry Co., Ltd. Composition for Improving Brain Function
EP3574020B1 (en) 2017-07-18 2024-05-15 The University of British Columbia Antibodies to amyloid beta
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
EP3778875A1 (en) 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
BR112023001061A2 (pt) 2020-07-23 2023-04-04 Othair Prothena Ltd Anticorpos antiabeta
CR20230253A (es) 2020-11-16 2023-07-26 Hoffmann La Roche Glucoformas de fab ricas en manosa
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
WO2024157085A1 (en) 2023-01-26 2024-08-02 Othair Prothena Limited Methods of treating neurological disorders with anti-abeta antibodies
CN117783359A (zh) * 2023-12-28 2024-03-29 中国计量科学研究院 一种基于串联质谱的转基因蛋白多靶同检方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
JP2780507B2 (ja) * 1991-03-29 1998-07-30 松下電器産業株式会社 内燃機関用フィルタ再生装置
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
GB9416007D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
WO1996039628A1 (en) * 1995-06-06 1996-12-12 Stemcell Therapeutics L.L.C. GLYCOPROTEIN gp105 ON BL3 HEMATOPOIETIC STEM CELLS
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
NZ514414A (en) * 1999-03-04 2004-02-27 Praecis Pharm Inc Modulators of beta-amyloid peptide aggregation comprising D-amino acids
WO2000077178A1 (en) 1999-06-16 2000-12-21 Boston Biomedical Research Institute IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
AU6722300A (en) 1999-08-31 2001-03-26 Ramot University Authority For Applied Research And Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
CA2388559A1 (en) 1999-11-29 2001-06-07 Neurochem Inc. Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP1125905A1 (en) 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
CZ2008595A3 (cs) 2000-02-24 2017-05-03 Washington University Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci
CA2313828A1 (en) 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ATE385811T1 (de) 2000-12-19 2008-03-15 Palatin Technologies Inc Identifizierung zielgerichteter faltungsstellen in peptiden und proteinen
DE60229051D1 (de) 2001-04-30 2008-11-06 Lilly Co Eli Humanisierte antikörper
DE60230736D1 (de) 2001-04-30 2009-02-26 Lilly Co Eli HUMANISIERTE ANTIKÖRPER DIE DAS BETA-AMYLOID PEPTID ERKENNEN& x9;
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
PT1944040E (pt) * 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1633786A4 (en) 2002-10-09 2007-07-25 Rinat Neuroscience Corp METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PT1960428E (pt) * 2005-12-12 2011-10-07 Hoffmann La Roche Anticorpos glicosilados na região variável contra beta-amilóide 4
PE20081477A1 (es) * 2006-12-11 2008-10-18 Hoffmann La Roche Formulacion liofilizada mab abeta

Also Published As

Publication number Publication date
NZ568241A (en) 2011-08-26
PE20071002A1 (es) 2007-11-19
US20150165022A1 (en) 2015-06-18
RS52004B (en) 2012-04-30
EP1960428A1 (en) 2008-08-27
NO20082874L (no) 2008-08-28
CR10000A (es) 2008-07-29
AU2006326301B2 (en) 2011-04-21
ATE517923T1 (de) 2011-08-15
EP2377886A1 (en) 2011-10-19
RU2008128138A (ru) 2010-01-20
JO2824B1 (en) 2014-09-15
ES2368591T3 (es) 2011-11-18
UY30003A1 (es) 2007-08-31
KR101401159B1 (ko) 2014-05-29
AU2006326301A1 (en) 2007-06-21
BRPI0619605A8 (pt) 2019-01-15
CA2632828A1 (en) 2007-06-21
WO2007068429A1 (en) 2007-06-21
EP1960428B1 (en) 2011-07-27
AR057233A1 (es) 2007-11-21
CY1114783T1 (el) 2016-12-14
HK1130066A1 (en) 2009-12-18
TWI382990B (zh) 2013-01-21
RU2438706C2 (ru) 2012-01-10
US9272031B2 (en) 2016-03-01
US8906370B2 (en) 2014-12-09
BRPI0619605A2 (pt) 2011-10-11
CN101351476A (zh) 2009-01-21
CN102659943B (zh) 2015-07-01
DOP2006000278A (es) 2007-07-15
BRPI0619605B1 (pt) 2019-08-13
MY155286A (en) 2015-09-30
MA30038B1 (fr) 2008-12-01
DK1960428T3 (da) 2011-08-22
IL191004A (en) 2013-08-29
CA2632828C (en) 2012-07-10
JP2009520691A (ja) 2009-05-28
KR20120089483A (ko) 2012-08-10
UA99097C2 (ru) 2012-07-25
PL1960428T3 (pl) 2012-02-29
PE20100748A1 (es) 2010-11-12
US20090252724A1 (en) 2009-10-08
BRPI0619605B8 (pt) 2021-05-25
SI1960428T1 (sl) 2011-10-28
PE20100684A1 (es) 2010-10-04
CN101351476B (zh) 2013-04-03
JP5145241B2 (ja) 2013-02-13
ZA200805038B (en) 2009-06-24
KR20080077132A (ko) 2008-08-21
ECSP088524A (es) 2008-07-30
NO346105B1 (no) 2022-02-21
PT1960428E (pt) 2011-10-07
TW200736273A (en) 2007-10-01
CN102659943A (zh) 2012-09-12

Similar Documents

Publication Publication Date Title
HK1130066A1 (en) Antibody glycosylation in the variable region
HK1218126A1 (zh) 抗體
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
GB0503546D0 (en) Antibody
IL187316A0 (en) Anti-interleukin 2 antibodies
ZA200709105B (en) Protein glycosylation
GB0502992D0 (en) The ballcaster
GB0523899D0 (en) The one
GB0511610D0 (en) The motor-roll-off
PL376079A1 (pl) Piec akumulacyjny obiektu
GB0516424D0 (en) Improvement in the lamp
GB0526162D0 (en) The gift
GB0500400D0 (en) Antibody
GB0521054D0 (en) The chew-it-bar
GB0524595D0 (en) The guillospade
GB0511228D0 (en) The cat-lock
GB0500175D0 (en) The astrocelesphere
GB0511718D0 (en) The texer
GB0502412D0 (en) The sproke
GB0521243D0 (en) The grapler
GB0519318D0 (en) The wheelbox
GB0506202D0 (en) The uni-tray
GB0517209D0 (en) The wayfinder